OptimizeRx (OPRX) director receives 13,060 restricted stock units grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Presti Mariyamma Varghese reported acquisition or exercise transactions in this Form 4 filing.

OptimizeRx Corp director Mariyamma Varghese Presti reported an award of equity-based compensation. She received 13,060 restricted stock units representing a contingent right to receive shares of OptimizeRx common stock, granted at no cash cost on May 1, 2026.

The restricted stock units will vest in full on the first anniversary of the grant date. Following this grant, the filing shows direct ownership of 13,060 shares or share equivalents tied to this award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Presti Mariyamma Varghese

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	13,060	$0.00	--

Holdings After Transaction: Common Stock — 13,060 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 13,060 units Grant date: May 1, 2026 Vesting schedule: Full vesting after 1 year +2 more

5 metrics

RSUs granted 13,060 units Restricted stock units representing OptimizeRx common stock

Grant date May 1, 2026 Date of restricted stock unit award

Vesting schedule Full vesting after 1 year Vests in full on first anniversary of grant

Price per share $0.00 No cash cost for RSU grant

Shares after transaction 13,060 shares or equivalents Total direct holdings following the grant

Key Terms

restricted stock units, contingent right, vest in full, common stock

4 terms

restricted stock units financial

"Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"representing a contingent right to receive shares of OptimizeRx common stock."

vest in full financial

"The restricted stock units will vest in full on the first anniversary of the date of the grant."

common stock financial

"contingent right to receive shares of OptimizeRx common stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/10/2026 - 01:18 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Presti Mariyamma Varghese

(Last)

(First)

(Middle)

C/O OPTIMIZERX CORPORATION

260 CHARLES STREET, SUITE 302

(Street)

WALTHAM

MASSACHUSETTS

02453

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OptimizeRx Corp [ OPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/01/2026		A		13,060	A	$0	13,060⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on the first anniversary of the date of the grant.

Remarks:

The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.

	/s/ Marion Odence-Ford, by Power of Attorney	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did OptimizeRx (OPRX) director Mariyamma Varghese Presti report in this Form 4?

She reported receiving 13,060 restricted stock units tied to OptimizeRx common stock. The award is equity-based compensation, granted at no cash cost, and reflects a grant or award acquisition rather than an open-market stock purchase.

How many OptimizeRx (OPRX) shares or units were granted in this transaction?

The filing shows a grant covering 13,060 restricted stock units. Each unit represents a contingent right to receive one share of OptimizeRx common stock, subject to vesting conditions described in the award’s terms and the Form 4 footnote.

When do the granted restricted stock units for OptimizeRx (OPRX) vest?

The restricted stock units will vest in full on the first anniversary of the grant date. This means the entire 13,060-unit award is scheduled to fully vest one year after May 1, 2026, assuming applicable conditions are satisfied.

Did the OptimizeRx (OPRX) director pay anything for the 13,060-unit award?

No cash payment was made for this award; the reported price per share is zero. This indicates the 13,060 restricted stock units were granted as compensation rather than purchased in the market, consistent with a typical equity incentive grant.

What is the director’s reported OptimizeRx (OPRX) holding after this award?

The Form 4 shows total direct holdings of 13,060 shares or share equivalents following the transaction. This amount corresponds to the granted restricted stock units, which convert into common stock upon vesting on the schedule described.

Is this OptimizeRx (OPRX) Form 4 transaction a buy or a sale in the market?

It is not a market buy or sale. The transaction is coded as a grant or award acquisition, reflecting 13,060 restricted stock units of OptimizeRx common stock issued as compensation, rather than an open-market purchase or disposition of existing shares.